title: Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia.
abstract: Frontotemporal lobar degeneration (FTLD) refers to a focal, non-Alzheimer form of cerebral degeneration that encompasses the distinct clinical syndromes of frontotemporal dementia (FTD), progressive non-fluent aphasia (PNFA) and semantic dementia. Some patients show tau-based pathological changes and in familial cases mutations have been identified in the microtubule-associated protein tau gene (MAPT) on chromosome 17q21. However, many cases are tau-negative, showing instead ubiquitin-immunoreactive (UBQ-ir) neuronal cytoplasmic inclusions and neurites, and in some familial cases UBQ-ir neuronal intranuclear inclusions of a lentiform appearance. Very recently, mutations have been identified in familial cases in the progranulin (PGRN) gene, also on chromosome 17q21. Clinical, pathological and molecular diversity within FTLD highlights the importance of careful examination of clinical-pathological-genetic relationships. This paper reports, for the first time, a clinico-pathological investigation of two FTLD families with PGRN mutations, and compares the clinical characteristics with those of patients studied in the department with MAPT mutations. The clinical profile associated with PGRN mutations constituted, in some patients, a prototypical picture of FTD and in others one of PNFA, both profiles occurring within the same family. Patients with PGRN mutations exhibited phonological deficits, whereas in patients with MAPT mutations language abnormalities, when present in addition to the prominent behavioural disorder, take the form of semantic disturbance. The findings provide compelling evidence for the link between FTD and PNFA, while raising the possibility of identifiable clinical differences between FTLD patients with MAPT and PGRN mutations.
authors.affiliation: Clinical Neuroscience Research Group, University of Manchester Salford, Manchester, UK.
authors.forename: J S
authors.initials: JS
authors.lastname: Snowden
authors.forename: S M
authors.initials: SM
authors.lastname: Pickering-Brown
authors.forename: I R
authors.initials: IR
authors.lastname: Mackenzie
authors.forename: A M T
authors.initials: AM
authors.lastname: Richardson
authors.forename: A
authors.initials: A
authors.lastname: Varma
authors.forename: D
authors.initials: D
authors.lastname: Neary
authors.forename: D M A
authors.initials: DM
authors.lastname: Mann
mesh_terms: D000368:Aged; D001039:Aphasia, Broca / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000523:psychology; D001931:Brain Mapping / Q000379:methods; D003072:Cognition Disorders / Q000209:etiology / Q000473:pathology; D003704:Dementia / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000523:psychology; D018450:Disease Progression; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics* / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009483:Neuropsychological Tests; D010375:Pedigree; D000077153:Progranulins; D013702:Temporal Lobe / Q000378:metabolism; D015899:Tomography, Emission-Computed, Single-Photon; D025801:Ubiquitin / Q000378:metabolism
chemical_list: C492314:GRN protein, human; D036341:Intercellular Signaling Peptides and Proteins; D000077153:Progranulins; D025801:Ubiquitin